Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed its forecast and conducted a sum-of-the-parts analysis. The investor debate is shifting towards ALKS 2680, which will gain greater attention into the Phase 2 readouts in the second half of 2025, given its potential to be disruptive in the $10B branded narcolepsy and idiopathic hypersomnia markets, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter